- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02907697
Adherence Intervention for HIV-infected Drug Users
July 22, 2022 updated by: Kasey Claborn, University of Texas at Austin
Many people living with HIV use illicit drugs, which leads to worsened health outcomes and increased transmission of HIV due to poor adherence to medication regimens.
This research will develop an intervention targeting medication adherence that is tailored to the unique needs of HIV-infected drug users.
This research will promote adherence and improve treatment outcomes among HIV-infected drug users thereby minimizing the development of drug resistant strains of HIV and reducing transmission.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This K23 research and training award advances the long-term goal of improving treatment outcomes and reducing transmission of HIV among HIV-infected drug users.
The proposed training and research plans will enable the PI to develop the skills needed for an independent research career in the area of illicit drug use and HIV adherence intervention.
The objective of this award is to develop skills in implementation science, behavioral intervention development and evaluation with drug using populations, and in-depth qualitative data analysis to accelerate refinement and effective implementation of interventions for HIV-infected drug users.
Multiple comorbidities such as drug use and HIV act synergistically to produce poorer health outcomes and increase morbidity, mortality, and transmission of HIV.
Consequently, effective and sustainable interventions adapted to drug users to improve antiretroviral medication adherence and reduce risk behaviors are urgently needed.
Drug users present unique treatment challenges compared with other HIV-infected populations, including lower rates of adherence and inferior treatment outcomes.
Additionally, interpersonal factors, including social support, negative patient-provider interactions, and socioeconomic challenges present significant barriers to adherence.
Thus, the generalizability of current adherence interventions to drug users is limited, and there is a pressing need for efficacious interventions adapted to HIV-infected drug using populations.
This project addresses this gap by being the first to adapt and test the acceptability and efficacy of a combined adherence and brief motivational intervention for HIV-infected drug users.
Specifically, the intervention will augment the established Life Steps adherence intervention to include: (1) a tailored Life Steps module addressing the unique needs of illicit drug users, aimed at improving medication adherence; (2) a brief Motivational Interview to address drug use and other risk behaviors; and (3) two follow-up booster sessions.
A three-phase, top-down research approach to adapt, refine, and pilot test the intervention will be conducted.
Phase 1 will include focus groups with HIV-infected drug users currently prescribed antiretroviral medications and individual interviews with community-based clinicians.
Phase 2 will include manual development, therapist training, a pilot trial, in-depth qualitative interviews, and further manual revisions.
Phase 3 will include a small, 2-armed (intervention vs. health education control) randomized controlled trial with 60 HIV-infected drug users.
Feasibility, acceptability, and preliminary indication of improvement in antiretroviral adherence and reduction in drug use will be examined at 1-, 3-, and 6-month follow-ups.
To enable the PI to pursue this long-term research agenda, she will work with experienced mentors to build three areas of expertise: (1) proficiency in qualitative research methods and analysis; (2) skills in intervention development and evaluation with illicit drug using populations; (3) expertise in advanced longitudinal data analysis; and (4) implementation science.
This K23 study addresses a key priority in HIV treatment science, and it will fully prepare the PI for an independent research career as an HIV intervention scientist.
Study Type
Interventional
Enrollment (Anticipated)
132
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Austin, Texas, United States, 78712
- Unviersity of Texas Dell Medical School
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- over 18 years of age
- HIV-infected
- prescribed an antiretroviral regimen
- meet DSM-V criteria for a substance use disorder (other than tobacco and alcohol) and report ≥3 days of use of an illicit drug per month over the past 90 days.
- self-report <100% adherence and have experienced a detectable viral load (>20 copies/mL) within the last 6 months.
Exclusion Criteria:
- cognitive impairments that jeopardize informed consent
- active psychosis
- current suicidal ideation
- not fluent in English
- have a prescription for and report only medicinal use of marijuana
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LifeSteps-Drug Use
The investigators expect the LifeSteps-Drug Use adaptation will be modeled after the Life Steps adherence intervention with the addition of a Drug Use module based on motivational interviewing and the FRAMES approach.
The LifeSteps-Drug Use intervention is expected to include two in-person sessions and two telephone booster sessions.
While anticipated preliminary adaptations have been based on the extant literature, changes to the protocol will be based on data obtained during the qualitative phase which will be sufficiently broad and open to assess for factors that we have not anticipated.
|
|
Active Comparator: Health Education
The health education condition is a time-matched, active control arm.
It will consist of two in-person sessions and two telephone sessions.
Each session will cover a general health education topic.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Antiretroviral Adherence
Time Frame: 1-, 3-, and 6-months
|
Change in Antiretroviral Adherence will be assessed by use of medical event monitoring systems (MEMS).
MEMS is a pill-bottle-cap with a pressure activated chip which records time/date the bottle is opened.
MEMS data will be collected on one antiretroviral medication following a triage criterion established in studies of antiretroviral adherence.
|
1-, 3-, and 6-months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Center for Epidemiologic Studies Depression Scale (CES-D)
Time Frame: 1-, 3-, and 6-months
|
Change in depression over time will be assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) is a widely used 20-item measure and has good sensitivity and specificity and high internal consistency and has been used extensively with PLWH and is related to ART adherence.
|
1-, 3-, and 6-months
|
HIV Treatment Adherence Self-Efficacy (HIV-ASES)
Time Frame: 1-, 3-, and 6-months
|
Change in treatment self-efficacy will be assessed using the HIV-ASES whic is a 12-item scale of patient confidence in their ability to carry out behaviors related to adhering to medication regimens.
|
1-, 3-, and 6-months
|
U.S. Health Resources and Service Administration measure of HIV treatment retention
Time Frame: 1-, 6-months
|
Change in HIV Treatment Retention will be measured with the U.S. Health Resources and Service Administration measure of HIV treatment retention, which defines treatment retention as having at least two outpatient visits separated by at least 90 days during a 12-month period
|
1-, 6-months
|
Risk Assessment Battery
Time Frame: 1-, 3-, and 6-months
|
Change in HIV risk behavior will be assessed using the Risk Assessment Battery which assesses HIV risk behavior, including sex risk and drug risk, in the past six months.
|
1-, 3-, and 6-months
|
HIV1 Ultra RT PCR-Roche test
Time Frame: 1-, 3-, and 6-months
|
This lab assay will be used to assess change in HIV viral load over time.
|
1-, 3-, and 6-months
|
Urine Toxicology Screens
Time Frame: 1-, 3-, and 6-months
|
Participants will be asked to give a urine sample at each assessment.
Redwood Toxicology Redi-cups urine drug screens have test strips in the specimen lids allowing for fast screening without spillage.
The Redi-cups 5-panel urine drug screen tests for cocaine, THC, methamphetamines, opiates, and benzodiazepines.
This will provide biological verification of drug use to assess change in drug use over time.
|
1-, 3-, and 6-months
|
ACTG Self-Reported Antiretroviral Medication Adherence
Time Frame: 1-, 3-, and 6-months
|
The ACTG scale will be used to assess self-reported adherence to antiretroviral medications.
|
1-, 3-, and 6-months
|
30-day Timeline Followback (TLFB)
Time Frame: 1-, 3-, and 6-months
|
The TLFB will be used to assess change in alcohol, tobacco, and illicit drugs over time.
|
1-, 3-, and 6-months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Kasey Claborn, PhD, The Unviersity of Texas
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2016
Primary Completion (Anticipated)
October 1, 2022
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
August 26, 2016
First Submitted That Met QC Criteria
September 14, 2016
First Posted (Estimate)
September 20, 2016
Study Record Updates
Last Update Posted (Actual)
July 25, 2022
Last Update Submitted That Met QC Criteria
July 22, 2022
Last Verified
July 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- K23DA039037 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on Life Steps-Drug Use
-
University of California, San FranciscoNational Institute of Nursing Research (NINR)Completed
-
Rush University Medical CenterEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Roswell Park Cancer InstituteCompletedPlasma Cell MyelomaUnited States
-
Oklahoma State University Center for Health SciencesCompleted
-
Fenway Community HealthMassachusetts General Hospital; Brown University; Emory University; University... and other collaboratorsCompletedHIV | Medication Adherence | Pre-exposure ProphylaxisUnited States
-
Massachusetts General HospitalRyerson University; The Fenway InstituteCompletedHIV/AIDS | TraumaUnited States, Canada
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA)CompletedDepression | Substance UseUnited States
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Helse Midt-Norge; Sykehusapotekene i Midt NorgeCompletedStroke | Ischemic Attack, TransientNorway
-
National Institute on Drug Abuse (NIDA)CompletedAdolescent BehaviorUnited States
-
Makerere UniversityHarvard Medical School (HMS and HSDM); Massachusetts General Hospital; University...CompletedPrEP | HIV | Transgender Women | Sexually Transmitted Diseases, BacterialUganda